NCT03511300 (ACE) is a NA clinical trial of Goal-Setting Instructions in Stroke, Ischemic, sponsored by Sunnybrook Health Sciences Centre.

Who is sponsoring NCT03511300?

NCT03511300 is sponsored by Sunnybrook Health Sciences Centre.

What drugs are being tested in NCT03511300?

Interventions in NCT03511300: Goal-Setting Instructions, Standard Instructions.

What condition does NCT03511300 study?

NCT03511300 studies Stroke, Ischemic.

Is NCT03511300 still recruiting?

NCT03511300 is currently completed. Last updated 29 October 2019.

Last reviewed 2019-10-29 · How we verify

NCT03511300: ACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ready, Set, Goal: Motivation and Cognition in Stroke Patients

Completed NA Last updated 29 October 2019

What this trial tests

NA trial testing Goal-Setting Instructions in Stroke, Ischemic in 72 participants. Completed in 25 October 2019.

Timeline

1 June 2018

Primary endpoint
1 October 2019

25 October 2019

Quick facts

Lead sponsor	Sunnybrook Health Sciences Centre
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	other
Enrollment	72
Start date	1 June 2018
Primary completion	1 October 2019
Estimated completion	25 October 2019
Sites	1 location across Canada

Drugs / interventions tested

Goal-Setting Instructions
Standard Instructions

Conditions studied

Stroke, Ischemic — all drugs for Stroke, Ischemic →

Sponsor

Sunnybrook Health Sciences Centre — full company profile →

Who can join

18 and older, any sex, with Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Apathy is a syndrome of reduced motivation, characterized by diminished goal-directed behaviours (e.g., lack of effort), decreased goal-oriented cognitions (e.g., lack of interest) and blunted affect. Apathy is present in 20-50% of individuals after experiencing a stroke. Despite the detrimental impact of reduced goal-directed behaviours and cognitions on activities of daily living and cognition in stroke patients, interventions for increasing motivation (reducing apathy) have yet to be examined in this population. This study will examine the effect of goal-setting instructions on cognitive performance in stroke patients. The investigators hypothesize that in stroke patients, goal-setting instructions will improve cognitive performance relative to standard instructions. If goal-setting instructions are effective in improving cognitive performance, it may indicate that treatments targeting apathy could serve as a novel way to improve cognitive outcomes and enhance patient quality of life post-stroke.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Goal Setting Improves Cognitive Performance in a Randomized Trial of Chronic Stroke Survivors.
Fishman KN, Ashbaugh AR, Swartz RH. · · 2021 · cited 12× · PMID 33467876 · DOI 10.1161/strokeaha.120.032131

Verify or expand the search:

Other recruiting trials for Stroke, Ischemic

Currently open trials in the same condition.

NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting

Other Sunnybrook Health Sciences Centre trials

Trials by the same sponsor.

NCT07478705 — Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid · NA · not yet recruiting
NCT07376018 — Ketogenic Diet and Neuromodulation in Treatment Resistant Depression · NA · not yet recruiting
NCT07350278 — Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therap · NA · not yet recruiting
NCT07191145 — Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) · Phase 3 · not yet recruiting
NCT07308587 — Evaluation of Intercostal Neuralgia in Patients With Chest Tube Insertion After Traumatic Rib Fracture · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03511300 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sunnybrook Health Sciences Centre
Last refreshed: 29 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03511300.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing